التفاصيل البيبلوغرافية
| العنوان: |
The non-steroidal anti-inflammatory drug salsalate provides safe and effective control of mucositis-unrelated pain during autologous and allogeneic hematopoietic stem cell transplantation. |
| المؤلفون: |
Trifilio, S., Gordon, L., Rubin, H., Grosshans, N., Mehta, J. |
| المصدر: |
Supportive Care in Cancer; Jul2021, Vol. 29 Issue 7, p3643-3648, 6p |
| مصطلحات موضوعية: |
MUCOSITIS, HEMATOPOIETIC stem cell transplantation, STEM cell transplantation, PAIN management, ANTI-inflammatory agents, BLOOD platelet transfusion, HOMOGRAFTS, PAIN, NONSTEROIDAL anti-inflammatory agents, IMMUNOSUPPRESSION, RETROSPECTIVE studies, SALICYLATES, PHARMACODYNAMICS |
| مستخلص: |
Introduction: Pain is a serious adverse event which frequently accompanies hematopoietic stem cell transplantation (HSCT). The safety and efficacy of NSAIDS during HSCT is currently unknown. Salsalate is a platelet-sparing NSAID with a favorable toxicity profile compared with other NSAIDS. We report the safety and efficacy of salsalate for different types of pain during SCT.Methods: We conducted a retrospective study of SCT recipients empirically treated with salsalate for > 48 h. Pain scores were assessed using the verbal rating scale for pain. A subset analysis of patients who received > 7 days of salsalate during periods of pancytopenia, mucositis, and other end-organ toxicities is included.Results: Sixty-four patients, 42 auto- and 22 allografts, were identified. Reason for use: vertebral-related pain (30%), musculoskeletal (30%), and cytokine inflammatory pain syndromes (24%). Median dose 1500 mg/day, number of treatment days = 5, started on day+5 post-HSCT. Pain resolved/improved to pain score < 4 in 76% and stable in 15%. Forty-four patients (28-auto and 16 allografts) received > 7-day salsalate. Median WBC and platelet nadir were < 0.1 and 10,000 cells/ml respectively.Efficacy: pain was improved or eradicated in 64% and stable in 32%.Toxicity: LFT elevation (n = 2), elevated serum creatinine (n = 2), and minor bleed (n = 5-nose, gums, and urine). Salsalate discontinuation (n = 6): ineffective (n = 1), the liver (n = 1), the kidney (n = 1), > 5 platelet transfusions (n = 1), and vomiting (n = 2). There was no treatment related mortality. Salsalate was well tolerated, safe, and beneficial for several different types of pain during HSCT. [ABSTRACT FROM AUTHOR] |
|
Copyright of Supportive Care in Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
